Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial

BACKGROUND: Pharmacological therapies of proven efficacy in coronavirus disease 2019 (COVID-19) are still lacking. We have identified IFNβ-1a as the most promising drug to be repurposed for COVID-19. The rationale relies on the evidence of IFNβ anti-viral activity in vitro against SARS-CoV-2 and ani...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosi, Emanuele, Bosi, Carlo, Rovere Querini, Patrizia, Mancini, Nicasio, Calori, Giliola, Ruggeri, Annalisa, Canzonieri, Cecilia, Callegaro, Luciano, Clementi, Massimo, De Cobelli, Francesco, Filippi, Massimo, Bregni, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681191/
https://www.ncbi.nlm.nih.gov/pubmed/33225960
http://dx.doi.org/10.1186/s13063-020-04864-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681191/
https://www.ncbi.nlm.nih.gov/pubmed/33225960
http://dx.doi.org/10.1186/s13063-020-04864-4

Ejemplares similares